
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

39209972
70806
10.1038/s41598-024-70806-8
Article
Association between change in heart rate over years and life span in the Paris Prospective 1, the Whitehall 1, and Framingham studies
Gaye Bamba m.bamba.gaye@gmail.com

123
Valentin Eugenie 3
Xanthakis Vanessa 456
Perier Marie-Cecile 3
Celermajer David S. 7
Shipley Martin 8
Marijon Eloi 23
Song Rebecca J. 9
Empana Jean-Philippe 3
Ramachandran Vasan S. 469
Jouven Xavier 23
1 https://ror.org/04je6yw13 grid.8191.1 0000 0001 2186 9619 Alliance for Medical Research in Africa, Department of Medical Physiology, Cheikh Anta Diop University, Dakar, Senegal
2 https://ror.org/016vx5156 grid.414093.b 0000 0001 2183 5849 Department of Cardiology, Hôpital Européen Georges Pompidou, 20 Rue Leblanc, 75015 Paris, France
3 grid.462416.3 0000 0004 0495 1460 Université Paris Cité, PARCC, INSERM, Paris, France
4 https://ror.org/05qwgg493 grid.189504.1 0000 0004 1936 7558 Section of Preventive Medicine and Epidemiology, Department of Medicine, Boston University, Boston, MA USA
5 https://ror.org/05qwgg493 grid.189504.1 0000 0004 1936 7558 Department of Biostatistics, Boston University School of Public Health, Boston, MA USA
6 https://ror.org/031grv205 grid.510954.c 0000 0004 0444 3861 Framingham Heart Study, Framingham, MA USA
7 https://ror.org/0384j8v12 grid.1013.3 0000 0004 1936 834X Sydney Medical School, University of Sydney, Sydney, Australia
8 https://ror.org/02jx3x895 grid.83440.3b 0000 0001 2190 1201 Department of Epidemiology and Public Health, University College London, 1-19 Torrington Place, London, WC1E 6BT UK
9 https://ror.org/05qwgg493 grid.189504.1 0000 0004 1936 7558 Department of Epidemiology, Boston University School of Public Health, Boston, MA USA
29 8 2024
29 8 2024
2024
14 2005230 5 2023
21 8 2024
© The Author(s) 2024, corrected publication 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Heart rate, a measure of the frequency of the cardiac cycle, reflects the health of the cardiovascular system, metabolic rate, and activity of the autonomic nervous system. Whether changes in resting heart rate are related to lifespan has not yet been explored to our best knowledge. In this study, we examined the association between resting heart rate and lifespan using linear regression in the Paris Prospective Study I, the Whitehall I Study, and the Framingham Heart Study. We used Cox proportional hazards regression to relate changes in heart rate over years to mortality risk. We observed a statistically significant association between increases in resting heart rate over a 5-year period and risk of mortality in the Paris Prospective Study I (HR mortality per 10 bpm increase over time: 1.20; 95% CI: 1.13 to 1.27) and over an 8-year period in the Framingham Heart Study (HR: 1.13; 95% CI: 1.07 to 1.19 for men and HR: 1.09; 95% CI: 1.04 to 1.15 for women), after adjusting for classical risk factors and resting heart rate. Our study shows that men and women who increase their resting heart rate over time increase their risk of mortality.

Subject terms

Cardiology
Epidemiology
Ageing
issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Across mammalian species, larger body size is associated with lower heart rate and a longer life span1–3. Heart rate, a measure of the frequency of the cardiac cycle, reflects health of the cardiovascular system, metabolic rate, and activity of the autonomic nervous system. Evolution has shaped optimal body size and heart rate in various species across millennia such that there is a neat inverse association between the two. The astonishing increase in human life span in the past two centuries raises the question of whether the human species is an outlier in the inverse heart rate-life span association4. Improvements in health and social care underlie improvements in life span but there are concerns that the omnipresent obesogenic environment may undermine further progress. In the original Framingham Heart Study cohort of 5070 subjects, a greater death rate was observed in individuals with faster heart rate, who were free of cardiovascular disease at the entry of the study and followed for 30 years5. However, to our best knowledge, whether change in resting heart rate is related to lifespan has not been yet explored. This would be an important step to increase our knowledge on a potential causal relationship between HR and lifespan, which may have clinical and public health implications.

To understand the association between heart rate and lifespan, we had 2 aims: (1) to confirm the inverse association between resting heart rate and lifespan within human populations; and (2) to look for any association between increase in heart rate (over a 5-year period in the Paris Prospective Study I and an 8-year period in the Framingham Study) and risk of mortality in modern humans.

Results

We investigated whether differences in resting heart rate within human populations are associated with life span using data from three population-based cohorts based in three different countries: the Paris Prospective Study I (France, Fig. 1), the Whitehall I study (UK, Fig. 2), and the Framingham Heart Study (USA, Fig. 3). In the Paris Prospective Study I, among 7976 healthy French men aged 42 to 53 years, recruited in the study from 1967 to 1972, 2387 deaths were recorded by 31st December 1993. As expected, there was an inverse linear relation between resting heart rate and life span, which remained significant after adjustment for potential confounders. Subjects with a resting heart rate over 90 bpm had a life span of 70.27 ± 12.78 whereas subjects with a resting heart rate of less than 60 bpm had a life span of 79.30 ± 8.43 (HR mortality for 10 bpm difference: 1.25; 95% CI: 1.21 to 1.30; p < 0.0001) (Fig. 1), corresponding to an average difference in life span of 9 years.Figure 1 Relation between resting heart rate (at study baseline) and life span in 7967 men from the Paris Prospective study I.

Figure 2 Relation between resting heart rate (at study baseline) and life span in the 1226 men from the Whitehall I study.

Figure 3 Relation between resting heart rate (at study baseline) and life span in 3299 men (a) and 4001 women (b) from the Framingham Original and Offspring cohorts.

In the Whitehall I study, among the 1226 healthy British men aged 52 ± 7 years, recruited between 1967 and 1969, 977 had died at last follow up in 2008. Similar to the Paris Prospective Study I, an inverse resting heart rate-life span relation was also observed in both the unadjusted and adjusted models (Fig. 2).

The analysis in the Framingham Heart Study extended the results to women. The participants were recruited from 1971 to 1975. Among 4001 US women aged 47 ± 16 years, a total of 2409 deaths occurred over a mean follow-up time of 32.8 years. Among 3299 men aged 45 ± 15 years, a total of 2172 deaths occurred over a mean follow-up of 30.9 years. An inverse association was observed between resting heart rate and life span in both women and men. Women experienced longer longevity than men (5 years on average) for each category of resting heart rate (Fig. 3).

Furthermore, we examined the association between change in resting heart rate over a 5-year and 8-year period and risk of mortality using data from the 5589 men in the Paris Prospective Study I as well as 3299 men and 4001 women in the Framingham Heart Study (Table 1). We observed a statistically significant association between increase in resting heart rate over a 5-year period and risk of mortality in French men from the Paris Prospective Study I (HR mortality per 10 bpm increase over time: 1.20; 95% CI: 1.13 to 1.27) and over an 8-year period in American men and women from the Framingham Heart Study (HR: 1.13; 95% CI: 1.07 to 1.19 for men and HR: 1.09; 95% CI: 1.04 to 1.15 for women), after adjusting for classical risk factors and resting heart rate. This hypothesis was not tested out in the British cohort.Table 1 Multivariable-adjusted hazard ratios for change in heart rate over 5–8 years and risk of mortality in the Paris Prospective Study I and the Framingham Heart Study.

Cohort	Sex	Hazards ratio per 10 bpm increase	95% Confidence interval	p value	
PPSI	Male	1.20	(1.13, 1.27)	 < 0.0001	
FHS	Female	1.09	(1.04, 1.15)	0.0003	
Male	1.13	(1.07, 1.19)	 < 0.0001	
PPS I: A total of 1256 deaths among 5589 over a 25 years follow-up. Baseline follow up was at 1967.

FHS: A total of 1582 men and 1840 women had died over a mean follow-up of 30.9 years for men, and 32.8 years for women in 2461 men and 3068 women. Baseline follow up was between 1971 and 1975.

Heart rate change was determined using two measurements, the heart rate baseline and after 5 years in PPSI, and after 8 years in FHS.

Subjects whose resting heart rate increased by 10 bpm over a 5-year period for PPS I and 8-year period for FHS, increased their risk of mortality (p < 0.001).

Models are adjusted for age, smoking (mean consumption g/days 5 last years for PPS I; current smoking (yes/no) for FHS), diabetes, body mass index, physical activity, systolic blood pressure, and total blood cholesterol, and baseline heart rate.

Ethics declaration

All methods were carried out in accordance with relevant guidelines and regulations, informed consent was obtained from all subjects and/or their legal guardians.

Statistical analysis

Life span in all three cohorts was defined by age at death among participants who died over the follow-up period. For participants in the Paris Prospective and Whitehall studies who were alive at the end of the follow-up, life span was estimated based on national age and sex in the corresponding country.

Aim 1 and 2

As the sample size and number of deaths were larger in the Paris Prospective Study I and Framingham Study, heart rate was categorized into 5 groups: ≤ 60, 60–70, 70–80, 80–90, > 90 bpm. In the Whitehall I study smaller numbers led us to use 4 categories: ≤ 60, 60–70, 70–80, > 80 bpm. Participants with known or suspected cardiovascular disease or with any of the following conditions were excluded from the study: resting systolic blood pressure > 180 mm Hg, resting 12-lead standard electrocardiogram abnormality (Minnesota code). A linear regression was used to examine the association between resting heart rate and life span in each cohort study, first unadjusted and then adjusted for age, baseline body mass index, smoking, physical activity, diabetes, systolic blood pressure, and total cholesterol level.

Aim 2

In the Paris Prospective Study I and Framingham Heart Study, multivariable Cox proportional hazards regression models were used to assess the change in heart rate (over a 5-year period in the Paris Prospective Study I and 8-years period in the Framingham Study) and risk of mortality. These analyses were adjusted for the covariates used in aim 2 along with resting heart rate at baseline. In the Paris Prospective Study, I, change in heart rate was defined as resting heart rate at the last follow-up visit minus resting heart rate at baseline. In the Framingham Heart Study, heart rate change (increase or decrease) was defined as resting heart rate at examination 16 (1979–1982) minus resting heart rate at examination 12 (1971–1974) for the Original cohort, and examination 2 (1979–1983) minus examination 1 for the Offspring cohort (1971–1975). A positive difference in heart rate indicated an increase in heart rate at the subsequent examination, while a negative difference indicated a decrease in heart rate.

SAS, Version 9.2 and 9.4 (Statistical Analysis System, Cary, N.C.) was used for analysis. P-values were 2-sided.

Discussion

In this study, using three long-term historical and large cohorts from France, UK and USA, we reported 2 main findings. We confirmed the inverse relation between resting heart rate and life span, firstly, within human populations. Secondly, we determined that men and women who increase their resting heart rate over a 5-year period in the Paris Prospective Study I and 8-years period in the Framingham Study, respectively, increase their risk of mortality.

The concept of total energy expenditure throughout the life span may be a part of the explanation of the association between heart rate and life span. Larger organisms lose heat as a function of their body surface area but generate heat as a function of their body mass. To conserve body temperature, smaller mammals with a higher surface area to mass ratio require an increased metabolic rate, which in turn determines heart rate. Thus, heart rate may be a “surrogate marker” for total energy expenditure, albeit much easier to measure accurately.

The same linear relation is observed between body size and longevity. Milnor proposed an explanation for the relation between heart rate, body size and aortic input impedance: the pulse wave length and arterial length are matched in a way that minimizes cardiac work6. The lower maximal rate in larger animals probably reflects the longer time required for propagation and reflection of pulse wave as heart rate size increases6. In our three studies, adjustments were performed for body mass index and did not alter the relation between heart rate and life span. In support of the key rate of energy expenditure as a determinant of mammalian life span, Rubner first noted in 1883 that total energy expenditure in a life span was approximately constant for 5 different species of domestic animal7. In 1994, Azbel determined little variation in the total number of heart beats per lifetime in non-human mammals and found that energy consumption per body atom, or per heartbeat, was relatively constant, at approximately 10 O2 molecules per atom per lifetime or approximately 10–8 O2 molecules per atom per heartbeat2. It is noteworthy, however, that fish and insects appear to have significantly fewer heart beats per life time than mammals (by approximately one order of magnitude), perhaps reflecting different environments and/or bioenergetic profiles.

Some experimental evidence has addressed the question of whether slowing heart rates in mammals might increase life span. Coburn et al.8 found that slowing heart rate in mice by approximately 50% (using the pharmacologic agent digoxin) increased life span by approximately 23%, however, this study was confounded by decreased body weight in the digoxin-treated mice. Beere et al.9 reported that lowering heart rate in monkeys (by surgical interference with the cardiac pacemaker cells) led to slowed development of coronary atherosclerosis. In humans, inducing a slow heart rate has only been studied in the context of serious illness. In this setting, using beta adrenergic receptor blocker have been associated with decreased mortality risk in post-myocardial infarction patients with heart failure and a high resting heart rate10,11. Furthermore, Fox et al.12 reported that although reduction in heart rate with ivabradine, a pure bradycardic If channel blocker agent, has been shown to decrease the incidence of coronary artery disease outcomes in a subgroup of patients who have heart rates of 70 bpm or higher, it has not been shown to improve cardiac outcomes in all patients with stable coronary artery diseases and left-ventricular systolic dysfunction. However, the effects of a slowing heart rate on life span have not been studied in a healthy human population, and causality has not been addressed.

In addition to the biological plausibility argument summarized above, assessing the causality in epidemiology requires 3 steps. The first step is observational, and in the present study, we show independent association between higher heart rate and shorter life span. The second step is also observational and we newly demonstrate that individuals who increase their heart rate over a 5-year period in the Paris Prospective Study I and 8-years period in the Framingham Study, respectively, decrease their life span. Importantly, these results were obtained in populations from different countries and different risk factors distribution supporting the generalizability of the findings. Also, the differences in lifespan according to baseline or change in resting heart rate were meaningful in magnitude, which supports the clinical and public health relevance of our findings. The third step is interventional: when an intervention decreases heart rate, we observe an increase in life span in the long run. We acknowledge that this step will be much more difficult to demonstrate. Still, on the basis of the present findings, and given the simplicity of heart rate assessment, heart rate might be a target to monitor humans health and life span. Given the obesogenic environment of our societies, creating favourable environment to promote healthy behaviours that impact heart rate (i.e. physical activity) is more than ever a priority.

It is important to mention that other trials have tackled this question with different findings, such as Whitehall II, that showed no association between changing heart rate and mortality. More investigations on this topic should prove useful to understanding the conclusions that should be drawn from the collective scene.

Online methods

Data

Paris prospective study I

This study is based on 7976 participants, aged 42 to 53 years, recruited to the study from 1967 to 1972 with a 93.4% response rate13,14. Briefly, oral informed consent was given by each participant, and the research protocol was approved by the institutional board, Commission Nationale Informatique et Liberté. Clinical examination consisted of electrocardiograms, physical examination, and collection of blood samples for laboratory tests; participants also responded to a questionnaire administered by trained interviewers. Resting heart rate was determined by measurement of the radial pulse during a one-minute recording, after a five-minute rest in supine position. The covariates assessed were age, smoking (mean consumption g/days over the 5 last years), diabetes (self-report of history of diabetes, whether treated), body mass index, current sport, systolic blood pressure, total cholesterol. Participants were invited back for a clinical examination each year for the following 4 years using the same procedure; a total of 5589 provided a heart rate at the final follow-up (five years from the baseline follow-up).

Mortality data were collected from medical records in hospital departments or general practitioners and death certificates. The end of the follow-up period was 1st January, 1994. The vital status could not be determined for 355 subjects (4.6%). The baseline characteristics of those 355 subjects lost to follow up and of those who did not complete the final follow-up examinations (five years from the baseline follow-up) were not different from the remaining 5589 men studied in the present analysis. Vital status was followed on all subjects until the last recorded survey in 1994 (25 years of average follow up), through the administrative department in charge of the study population until retirement age and then thereafter via the French national death registry.

Whitehall I study

Data were collected from 19,019 male London-based government employees aged 40 to 69 at screening between 1967 and 1970, with a 77% response rate. Participants provided informed written consent and research ethics approval was obtained from the National Health Service London—Harrow Research Ethics Committee. Screening involved the completion of a study questionnaire and participation in a medical examination, both of which have been described in detail elsewhere15. Heart rate was measured in a random subset of 1263 men (mean age 52, SD 7 years) in whom radiologic heart volume was calculated16. The covariates assessed in this age, smoking, diabetes, body mass index, current sport, systolic blood pressure, total cholesterol.

All cohort participants were traced using the National Health Service Central Registry for mortality for 40 years until 31st October 2008 by which time 977 men had died.

Framingham heart study

The final sample size for the current investigation consisted of 7300 participants (3299 men and 4001 women) from the Original (Examination 12, 1971–1974) and Offspring (Examination 1, 1971–1975) cohorts in the Framingham Heart Study after exclusion of participants < 20 years of age (n = 245), with prevalent cardiovascular disease (n = 698), or a systolic blood pressure > 180 mm Hg (n = 198). Heart rate was measured by echocardiogram and data on covariates (age, sex, systolic blood pressure, current smoking, diabetes status, body mass index, physical activity index, and total cholesterol level) were drawn from the same wave. Written informed consent was provided by all participants and the study protocol was approved by the Boston University Medical Center Institutional Review Board.

Death were confirmed from death certificates and supporting information was obtained from hospital records17. Participants were followed until 31st December 2017, an average follow-up of 30.9 years for men and 32.8 for women.

Author contributions

BG and XJ had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: BG, XJ Acquisition, analysis, or interpretation of data: BG, EV, VX, MCP, DSC, MS, EM, RJS, JPE, VSR, XJ Drafting of the manuscript: BG Critical revision of the manuscript for important intellectual content: BG, EV, VX, MCP, DSC, MS, EM, RJS, JPE, VSR, XJ Study supervision: BG, XJ Additional Information Competing financial interests: The authors declare no competing financial interests.

Competing interests

The authors declare no competing interests.

The original online version of this Article was revised: The original version of this Article contained errors in the Discussion. It now reads: "In this study, using three long-term historical and large cohorts from France, UK and USA, we reported 2 main findings. We confirmed the inverse relation between resting heart rate and life span, firstly, within human populations. Secondly, we determined that men and women who increase their resting heart rate over a 5-year period in the Paris Prospective Study I and 8-years period in the Framingham Study, respectively, increase their risk of mortality."

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Change history

9/6/2024

A Correction to this paper has been published: 10.1038/s41598-024-72000-2
==== Refs
References

1. Levine HJ Rest heart rate and life expectancy J. Am. Coll. Cardiol. 1997 30 1104 1106 9316546
Levine, H. J. Rest heart rate and life expectancy. J. Am. Coll. Cardiol. 30, 1104–1106 (1997).9316546
2. Azbel MYa Universal biological scaling and mortality Proc. Natl. Acad. Sci. U. S. A. 1994 91 12453 12457 10.1073/pnas.91.26.12453 7809058
Azbel, MYa. Universal biological scaling and mortality. Proc. Natl. Acad. Sci. U. S. A. 91, 12453–12457 (1994).7809058 10.1073/pnas.91.26.12453
3. Zhang GQ Zhang W Heart rate, lifespan, and mortality risk Ageing Res. Rev. 2009 8 52 60 10.1016/j.arr.2008.10.001 19022405
Zhang, G. Q. & Zhang, W. Heart rate, lifespan, and mortality risk. Ageing Res. Rev. 8, 52–60 (2009).19022405 10.1016/j.arr.2008.10.001
4. Oeppen J DEMOGRAPHY: Enhanced: Broken Limits to Life Expectancy Science 2002 296 1029 1031 10.1126/science.1069675 12004104
Oeppen, J. DEMOGRAPHY: Enhanced: Broken Limits to Life Expectancy. Science 296, 1029–1031 (2002).12004104 10.1126/science.1069675
5. Kannel WB Kannel C Paffenbarger RS Cupples LA Heart rate and cardiovascular mortality: The Framingham Study Am. Heart J. 1987 113 1489 1494 10.1016/0002-8703(87)90666-1 3591616
Kannel, W. B., Kannel, C., Paffenbarger, R. S. & Cupples, L. A. Heart rate and cardiovascular mortality: The Framingham Study. Am. Heart J. 113, 1489–1494 (1987).3591616 10.1016/0002-8703(87)90666-1
6. Milnor WR Aortic wavelength as a determinant of the relation between heart rate and body size in mammals Am. J. Physiol.-Regul. Integr. Comp. Physiol. 1979 237 R3 R6 10.1152/ajpregu.1979.237.1.R3
Milnor, W. R. Aortic wavelength as a determinant of the relation between heart rate and body size in mammals. Am. J. Physiol.-Regul. Integr. Comp. Physiol. 237, R3–R6 (1979).10.1152/ajpregu.1979.237.1.R3
7. Rubner M Ueber den Einfluss der Körpergrösse auf Stoff- und Kraftwechsel Z. Für Biol. 1883 19 535 562
Rubner, M. Ueber den Einfluss der Körpergrösse auf Stoff- und Kraftwechsel. Z. Für Biol. 19, 535–562 (1883).
8. Coburn AF Grey RM Rivera SM Observations on the relation of heart rate, life span, weight and mineralization in the digoxin-treated A-J mouse Johns Hopkins Med. J. 1974 128 169 193 4823320
Coburn, A. F., Grey, R. M. & Rivera, S. M. Observations on the relation of heart rate, life span, weight and mineralization in the digoxin-treated A-J mouse. Johns Hopkins Med. J. 128, 169–193 (1974).4823320
9. Beere PA Glagov S Zarins CK Retarding effect of lowered heart rate on coronary atherosclerosis Science 1984 226 180 182 10.1126/science.6484569 6484569
Beere, P. A., Glagov, S. & Zarins, C. K. Retarding effect of lowered heart rate on coronary atherosclerosis. Science 226, 180–182 (1984).6484569 10.1126/science.6484569
10. Zhang D Shen X Qi X Resting heart rate and all-cause and cardiovascular mortality in the general population: A meta-analysis Can. Med. Assoc. J. 2016 188 E53 E63 10.1503/cmaj.150535 26598376
Zhang, D., Shen, X. & Qi, X. Resting heart rate and all-cause and cardiovascular mortality in the general population: A meta-analysis. Can. Med. Assoc. J. 188, E53–E63 (2016).26598376 10.1503/cmaj.150535
11. Lechat P Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial Circulation 2001 103 1428 1433 10.1161/01.CIR.103.10.1428 11245648
Lechat, P. et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial. Circulation 103, 1428–1433 (2001).11245648 10.1161/01.CIR.103.10.1428
12. Fox K Ford I Steg PG Tendera M Ferrari R Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A randomised, double-blind, placebo-controlled trial The Lancet 2008 372 807 816 10.1016/S0140-6736(08)61170-8
Fox, K., Ford, I., Steg, P. G., Tendera, M. & Ferrari, R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A randomised, double-blind, placebo-controlled trial. The Lancet 372, 807–816 (2008).10.1016/S0140-6736(08)61170-8
13. Jouven X Heart-rate profile during exercise as a predictor of sudden death N. Engl. J. Med. 2005 352 1951 1958 10.1056/NEJMoa043012 15888695
Jouven, X. et al. Heart-rate profile during exercise as a predictor of sudden death. N. Engl. J. Med. 352, 1951–1958 (2005).15888695 10.1056/NEJMoa043012
14. Ducimetiere P Cambien F Richard JacquesL Rakotovao R Claude JeanR Coronary heart disease in middle-aged frenchmen The Lancet 1980 315 1346 1350 10.1016/S0140-6736(80)91796-1
Ducimetiere, P., Cambien, F., Richard, JacquesL., Rakotovao, R. & Claude, JeanR. Coronary heart disease in middle-aged frenchmen. The Lancet 315, 1346–1350 (1980).10.1016/S0140-6736(80)91796-1
15. Reid DD Cardiorespiratory disease and diabetes among middle-aged male civil servants The Lancet 1974 303 469 473 10.1016/S0140-6736(74)92783-4
Reid, D. D. et al. Cardiorespiratory disease and diabetes among middle-aged male civil servants. The Lancet 303, 469–473 (1974).10.1016/S0140-6736(74)92783-4
16. Christie D Physical correlates of radiologic heart volume Acta Radiol. Diagn. (Stockh.) 1978 19 732 736 10.1177/028418517801900503 717025
Christie, D. Physical correlates of radiologic heart volume. Acta Radiol. Diagn. (Stockh.) 19, 732–736 (1978).717025 10.1177/028418517801900503
17. Kannel, W. B., Wolf, P. A. & Garrison, R. J. Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. Section 34. Some Risk Factors Related to the Annual Incidence of Cardiovascular Disease and Death Using Pooled Repeated Biennial Measurements: Framingham Heart Study, 30-Year Follow-Up. Natl. Tech. Rep. Libr.- NTIS 474 (1987).
